Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant Pharmaceuticals International, a multinational pharmaceutical company, has acquired DermaTech, an Australian specialty pharmaceutical company, for approximately A$19 million, with customary adjustments for net asset value.
Subscribe to our email newsletter
This transaction is said to expand Valeant’s Australian specialty pharmaceutical business through the acquisition of key products in both the retail and prescription brands, which complement Valeant’s current product portfolio.